Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:SGEN
- CUSIP: 81257810
- Web: www.seattlegenetics.com
Capitalization:- Market Cap: $7.75748 billion
- Outstanding Shares: 142,716,000
Average Prices:- 50 Day Moving Avg: $58.25
- 200 Day Moving Avg: $62.04
- 52 Week Range: $42.58 - $75.36
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -50.83
- P/E Growth: -0.02
Sales & Book Value:- Annual Revenue: $416.12 million
- Price / Sales: 18.65
- Book Value: $4.23 per share
- Price / Book: 12.86
Profitability:- EBIDTA: ($162,430,000.00)
- Net Margins: -43.17%
- Return on Equity: -27.98%
- Return on Assets: -21.54%
Debt:- Current Ratio: 5.09%
- Quick Ratio: 4.62%
Misc:- Average Volume: 1.07 million shs.
- Beta: 2.4
- Short Ratio: 6.51
Frequently Asked Questions for Seattle Genetics (NASDAQ:SGEN)
What is Seattle Genetics' stock symbol?
Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."
How were Seattle Genetics' earnings last quarter?
Seattle Genetics, Inc. (NASDAQ:SGEN) announced its quarterly earnings results on Thursday, April, 27th. The company reported ($0.42) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.01. The firm earned $109.10 million during the quarter, compared to the consensus estimate of $103.23 million. Seattle Genetics had a negative net margin of 43.17% and a negative return on equity of 27.98%. The firm's revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.15) earnings per share. View Seattle Genetics' Earnings History.
When will Seattle Genetics make its next earnings announcement?
Where is Seattle Genetics' stock going? Where will Seattle Genetics' stock price be in 2017?
19 brokerages have issued 1 year price objectives for Seattle Genetics' shares. Their forecasts range from $38.00 to $80.00. On average, they expect Seattle Genetics' share price to reach $60.46 in the next year. View Analyst Ratings for Seattle Genetics.
What are analysts saying about Seattle Genetics stock?
Here are some recent quotes from research analysts about Seattle Genetics stock:
- 1. Cantor Fitzgerald analysts commented, "The Phase III ECHELON-1 study in previously untreated patients with advanced classical Hodgkin lymphoma met its primary endpoint of modified PFS (82.1% versus 77.2% at two years)." (6/26/2017)
- 2. Cowen and Company analysts commented, "SGEN announced this morning that following an interim safety look of 33A’s pivotal." (6/19/2017)
- 3. Cann analysts commented, "Seattle Genetics announced today that it is discontinuing the phase III CASCADE clinical trial of vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients. Seattle Genetics reported it took this action following consultation with the Independent Data Monitoring Committee (IDMC) and after reviewing unblinded data on June 16, 2017. As a result of the discontinuation of SGN-CD33A (vadastuximab talirine; 33A), we are removing estimated sales of SGN- CD33A from our model in 2020 and 2021." (6/19/2017)
- 4. J P Morgan Chase & Co analysts commented, "With top-line results for ECHELON-1 (Adcetris in 1L Hodgkin lymphoma) reading out at some point in 2017, we conducted a detailed analysis of the trial design and available data and interviewed a couple more KOLs to help frame expectations. We are also updating our model to better account for doc feedback and re-treatment rates among the various approved Adcetris settings. The bottom line is that we are bullish on the potential success of E-1 (70% in our model), which may offer a favorable trading opportunity into the data." (6/13/2017)
- 5. According to Zacks Investment Research, "Seattle Genetics missed bottom-line expectations in the first quarter of 2017 but sales came in ahead of estimates. With the recent llabel expansion of Keytruda in the lymphoma indication, investor focus will likely remain on Adcetris sales in the upcoming quarters. A decline in Adcetris sales will hurt the company's top line. Though, the company has a number of candidates in its pipeline, most of them are in early stages of development. Although the clinical hold on several early-stage trials of vadastuximab talirine in acute myeloid leukemia (AML) was lifted in Mar 2017, Seattle Genetics has a long way to go before the candidate comes close to commercialization. However, the company’s collaboration agreement with Takeda for the global development and commercialization of Adcetris is encouraging. Also, collaborations with companies like AbbVie, Bayer, Roche and Pfizer provide it with funds in the form of upfront, milestone and other payments." (5/2/2017)
Who are some of Seattle Genetics' key competitors?
Some companies that are related to Seattle Genetics include Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), Icon Plc (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Exact Sciences Corporation (EXAS), Galapagos NV (GLPG), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX) and Sage Therapeutics (SAGE).
Who are Seattle Genetics' key executives?
Seattle Genetics' management team includes the folowing people:
- Clay B. Siegall Ph.D., Chairman of the Board, President, Chief Executive Officer
- Todd E. Simpson, Chief Financial Officer
- Eric L. Dobmeier, Chief Operating Officer
- Jean I. Liu J.D., Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
- Darren S. Cline, Executive Vice President - Commercial
- Jonathan G. Drachman M.D., Chief Medical Officer, Executive Vice President - Research and Development
- Vaughn B. Himes Ph.D., Chief Technical Officer
- Felix J. Baker Ph.D., Lead Independent Director
- Srinivas Akkaraju M.D. Ph.D., Independent Director
- David W. Gryska, Independent Director
Who owns Seattle Genetics stock?
Seattle Genetics' stock is owned by many different of institutional and retail investors. Top institutional investors include
BAKER BROS. ADVISORS LP
(32.20%), Creative Planning (0.03%), Aperio Group LLC (0.02%), Capital Impact Advisors LLC (0.02%), Eqis Capital Management Inc. (0.02%) and Berson & Corrado Investment Advisors LLC (0.02%). Company insiders that own Seattle Genetics stock include Clay B Siegall, Darren S Cline, David W Gryska, Eric Dobmeier, Felix Baker, John A Orwin, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.
Who sold Seattle Genetics stock? Who is selling Seattle Genetics stock?
Seattle Genetics' stock was sold by a variety of institutional investors in the last quarter, including Creative Planning, Capital Impact Advisors LLC, Xact Kapitalforvaltning AB and Capstone Asset Management Co.. Company insiders that have sold Seattle Genetics stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.
Who bought Seattle Genetics stock? Who is buying Seattle Genetics stock?
Seattle Genetics' stock was purchased by a variety of institutional investors in the last quarter, including Mn Services Vermogensbeheer B.V., Fox Run Management L.L.C., US Bancorp DE, Meeder Asset Management Inc., Quantitative Systematic Strategies LLC, Assenagon Asset Management S.A., Berson & Corrado Investment Advisors LLC and Atria Investments LLC. Company insiders that have bought Seattle Genetics stock in the last two years include Felix Baker and John A Orwin. View Insider Buying and Selling for Seattle Genetics.
How do I buy Seattle Genetics stock?
Shares of Seattle Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seattle Genetics' stock price today?
One share of Seattle Genetics stock can currently be purchased for approximately $54.39.
MarketBeat Community Rating for Seattle Genetics (NASDAQ SGEN)MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Seattle Genetics (NASDAQ:SGEN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Sell Ratings, 10 Hold Ratings, 6 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.16) |
| Consensus Price Target: | $60.46 (11.16% upside) |
Analysts' Ratings History for Seattle Genetics (NASDAQ:SGEN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/26/2017 | William Blair | Reiterated Rating | Outperform | | High |  |
| 6/27/2017 | J P Morgan Chase & Co | Reiterated Rating | Neutral | | High | |
| 6/27/2017 | Piper Jaffray Companies | Reiterated Rating | Neutral | $48.00 | High | |
| 6/26/2017 | Cantor Fitzgerald | Reiterated Rating | Hold | $43.00 | High | |
| 6/23/2017 | Barclays PLC | Reiterated Rating | Hold | | Medium | |
| 6/21/2017 | Morgan Stanley | Lower Price Target | Overweight | $70.00 -> $64.00 | Medium | |
| 6/20/2017 | Needham & Company LLC | Reiterated Rating | Buy | $72.00 | Low | |
| 6/19/2017 | Cowen and Company | Reiterated Rating | Hold | $61.00 -> $54.00 | High | |
| 6/19/2017 | Cann | Reiterated Rating | Hold | | Low | |
| 6/15/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Hold | | Medium | |
| 4/28/2017 | HC Wainwright | Boost Price Target | Buy | $65.00 -> $75.00 | Low | |
| 4/7/2017 | Leerink Swann | Boost Price Target | Outperform | $70.00 -> $74.00 | Medium | |
| 3/16/2017 | CIBC | Initiated Coverage | Market Perform -> Market Perform | | Low | |
| 2/16/2017 | Bank of America Corporation | Downgrade | Neutral -> Underperform | | N/A | |
| 2/13/2017 | Credit Suisse Group | Boost Price Target | Neutral | $62.00 -> $66.00 | N/A | |
| 1/5/2017 | Royal Bank Of Canada | Set Price Target | Buy | $80.00 | N/A | |
| 1/5/2017 | Maxim Group | Reiterated Rating | Reduce | | N/A | |
| 9/16/2016 | Goldman Sachs Group, Inc. (The) | Downgrade | Neutral -> Sell | | N/A | |
| 7/27/2016 | SunTrust Banks, Inc. | Boost Price Target | Neutral | $34.00 -> $38.00 | N/A | |
(Data available from 7/23/2015 forward)
Earnings History for Seattle Genetics (NASDAQ:SGEN)Earnings History by Quarter for Seattle Genetics (NASDAQ SGEN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/24/2017 | | | | | | | | |
| 4/27/2017 | Q1 2017 | ($0.41) | ($0.42) | $103.23 million | $109.10 million | View | N/A | |
| 2/9/2017 | Q416 | ($0.34) | ($0.39) | $106.49 million | $105.30 million | View | Listen | |
| 10/27/2016 | Q316 | ($0.29) | ($0.23) | $4.34 million | $106.30 million | View | Listen | |
| 7/26/2016 | Q216 | ($0.32) | ($0.23) | $94.56 million | $95.40 million | View | Listen | |
| 4/28/2016 | Q116 | ($0.09) | ($0.15) | $116.49 million | $111.15 million | View | Listen | |
| 2/9/2016 | Q415 | ($0.20) | ($0.18) | $88.00 million | $93.50 million | View | N/A | |
| 10/29/2015 | Q315 | ($0.20) | ($0.21) | $82.35 million | $84.10 million | View | Listen | |
| 7/30/2015 | Q215 | ($0.26) | ($0.38) | $78.21 million | $77.10 million | View | Listen | |
| 4/30/2015 | Q1 | ($0.19) | ($0.17) | $74.57 million | $82.20 million | View | Listen | |
| 2/10/2015 | Q414 | ($0.25) | ($0.22) | $68.34 million | $74.30 million | View | Listen | |
| 10/30/2014 | Q314 | ($0.24) | ($0.13) | $66.90 million | $75.80 million | View | Listen | |
| 7/31/2014 | Q214 | ($0.23) | ($0.14) | $65.04 million | $68.30 million | View | Listen | |
| 5/1/2014 | Q114 | ($0.21) | ($0.13) | $64.62 million | $68.30 million | View | Listen | |
| 2/11/2014 | Q413 | ($0.24) | ($0.13) | $59.50 million | $67.40 million | View | Listen | |
| 11/5/2013 | Q313 | ($0.22) | ($0.19) | $57.79 million | $71.00 million | View | Listen | |
| 7/31/2013 | Q2 2013 | ($0.20) | ($0.06) | $58.12 million | $773.60 million | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.19) | ($0.14) | $53.72 million | $57.32 million | View | Listen | |
| 2/12/2013 | Q4 2012 | ($0.10) | ($0.09) | $57.21 million | $63.90 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.14) | ($0.12) | $52.79 million | $49.83 million | View | N/A | |
| 8/8/2012 | | ($0.15) | ($0.15) | | | View | N/A | |
| 5/8/2012 | | ($0.11) | ($0.11) | | | View | N/A | |
| 2/13/2012 | | ($0.31) | ($0.24) | | | View | N/A | |
| 11/3/2011 | | ($0.46) | ($0.35) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Seattle Genetics (NASDAQ:SGEN)2017 EPS Consensus Estimate: ($1.47)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.39) | ($0.39) | ($0.39) |
| Q2 2017 | 3 | ($0.44) | ($0.28) | ($0.37) |
| Q3 2017 | 4 | ($0.47) | ($0.19) | ($0.34) |
| Q4 2017 | 4 | ($0.50) | ($0.23) | ($0.37) |
(Data provided by Zacks Investment Research)
Dividend History for Seattle Genetics (NASDAQ:SGEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Seattle Genetics (NASDAQ:SGEN)Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 98.04%
Insider Trades by Quarter for Seattle Genetics (NASDAQ:SGEN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/5/2017 | Clay B. Siegall | CEO | Sell | 10,423 | $51.98 | $541,787.54 | |
| 6/22/2017 | Jonathan G Drachman | CMO | Sell | 10,000 | $64.01 | $640,100.00 | |
| 6/5/2017 | Clay B. Siegall | Insider | Sell | 10,423 | $65.21 | $679,683.83 | |
| 4/5/2017 | Clay B Siegall | Insider | Sell | 14,465 | $62.99 | $911,150.35 | |
| 3/31/2017 | Vaughn B Himes | Insider | Sell | 10,000 | $62.75 | $627,500.00 | |
| 3/6/2017 | Clay B Siegall | CEO | Sell | 14,465 | $68.04 | $984,198.60 | |
| 2/6/2017 | Clay B Siegall | Insider | Sell | 14,465 | $61.54 | $890,176.10 | |
| 1/6/2017 | Clay B. Siegall | Insider | Sell | 14,465 | $57.89 | $837,378.85 | |
| 12/13/2016 | Darren S. Cline | EVP | Sell | 10,000 | $63.38 | $633,800.00 | |
| 12/8/2016 | Eric Dobmeier | COO | Sell | 12,500 | $65.92 | $824,000.00 | |
| 12/7/2016 | Vaughn B. Himes | Insider | Sell | 30,000 | $65.32 | $1,959,600.00 | |
| 11/8/2016 | Felix Baker | Director | Buy | 382,500 | $59.36 | $22,705,200.00 | |
| 11/7/2016 | Clay B. Siegall | CEO | Sell | 14,465 | $58.43 | $845,189.95 | |
| 11/7/2016 | Marc E. Lippman | Director | Sell | 1,000 | $57.75 | $57,750.00 | |
| 11/3/2016 | Felix Baker | Director | Buy | 1,030,629 | $56.13 | $57,849,205.77 | |
| 11/1/2016 | Jonathan G. Drachman | CMO | Sell | 3,418 | $51.74 | $176,847.32 | |
| 10/6/2016 | Clay B. Siegall | Insider | Sell | 14,465 | $54.41 | $787,040.65 | |
| 9/22/2016 | Jonathan G Drachman | CMO | Sell | 2,249 | $56.75 | $127,630.75 | |
| 9/14/2016 | Eric Dobmeier | COO | Sell | 22,918 | $54.04 | $1,238,488.72 | |
| 9/13/2016 | Felix Baker | Director | Buy | 447,311 | $50.71 | $22,683,140.81 | |
| 9/8/2016 | Clay B. Siegall | Insider | Sell | 31,269 | $50.08 | $1,565,951.52 | |
| 9/8/2016 | Felix Baker | Director | Buy | 414,016 | $48.43 | $20,050,794.88 | |
| 8/23/2016 | Eric Dobmeier | COO | Sell | 12,589 | $48.00 | $604,272.00 | |
| 8/22/2016 | Clay B. Siegall | Insider | Sell | 23,381 | $46.59 | $1,089,320.79 | |
| 8/22/2016 | Eric Dobmeier | COO | Sell | 5,411 | $46.59 | $252,098.49 | |
| 8/22/2016 | Vaughn B. Himes | EVP | Sell | 3,991 | $46.59 | $185,940.69 | |
| 8/8/2016 | Clay B. Siegall | Insider | Sell | 11,660 | $47.19 | $550,235.40 | |
| 7/27/2016 | Clay B. Siegall | Insider | Sell | 4,042 | $45.20 | $182,698.40 | |
| 7/6/2016 | Clay B. Siegall | CEO | Sell | 7,618 | $40.56 | $308,986.08 | |
| 6/6/2016 | Clay B Siegall | CEO | Sell | 22,083 | $43.59 | $962,597.97 | |
| 6/2/2016 | Darren S Cline | EVP | Sell | 3,366 | $42.07 | $141,607.62 | |
| 5/27/2016 | Clay B Siegall | CEO | Sell | 48,660 | $40.41 | $1,966,350.60 | |
| 5/24/2016 | Clay B Siegall | CEO | Sell | 8,400 | $40.09 | $336,756.00 | |
| 5/23/2016 | Clay B Siegall | CEO | Sell | 6,700 | $40.12 | $268,804.00 | |
| 5/17/2016 | Clay B Siegall | CEO | Sell | 7,618 | $35.16 | $267,848.88 | |
| 4/25/2016 | Clay B Siegall | CEO | Sell | 800 | $40.00 | $32,000.00 | |
| 4/5/2016 | Clay B Siegall | CEO | Sell | 7,618 | $36.12 | $275,162.16 | |
| 3/22/2016 | Clay B Siegall | CEO | Sell | 15,236 | $35.52 | $541,182.72 | |
| 3/21/2016 | Clay B Siegall | CEO | Sell | 4,282 | $35.01 | $149,912.82 | |
| 3/17/2016 | Felix Baker | Director | Buy | 124,065 | $31.85 | $3,951,470.25 | |
| 3/16/2016 | Felix Baker | Director | Buy | 1,349,237 | $32.10 | $43,310,507.70 | |
| 3/15/2016 | Felix Baker | Director | Buy | 661,093 | $32.08 | $21,207,863.44 | |
| 3/14/2016 | Felix Baker | Director | Buy | 118,941 | $33.77 | $4,016,637.57 | |
| 3/11/2016 | Felix Baker | Director | Buy | 694,666 | $32.46 | $22,548,858.36 | |
| 3/8/2016 | Felix Baker | Director | Buy | 502,523 | $22.66 | $11,387,171.18 | |
| 3/2/2016 | Felix Baker | Director | Buy | 675,922 | $31.77 | $21,474,041.94 | |
| 3/1/2016 | Felix Baker | Director | Buy | 24,200 | $31.24 | $756,008.00 | |
| 2/29/2016 | Felix Baker | Director | Buy | 251,722 | $30.39 | $7,649,831.58 | |
| 2/26/2016 | Felix Baker | Director | Buy | 314,508 | $29.55 | $9,293,711.40 | |
| 2/22/2016 | Felix Baker | Director | Buy | 1,001,471 | $29.63 | $29,673,585.73 | |
| 2/17/2016 | Felix Baker | Director | Buy | 1,269,147 | $30.43 | $38,620,143.21 | |
| 2/12/2016 | John A. Orwin | Director | Buy | 2,000 | $28.33 | $56,660.00 | |
| 12/15/2015 | Vaughn B. Himes | EVP | Sell | 40,500 | $39.94 | $1,617,570.00 | |
| 12/3/2015 | Clay B. Siegall | CEO | Sell | 3,720 | $39.99 | $148,762.80 | |
| 11/20/2015 | Felix Baker | Director | Buy | 329,358 | $43.94 | $14,471,990.52 | |
| 11/17/2015 | Clay B Siegall | CEO | Sell | 87,473 | $45.40 | $3,971,274.20 | |
| 11/11/2015 | Darren S Cline | SVP | Sell | 5,769 | $45.68 | $263,527.92 | |
| 11/10/2015 | Felix Baker | Director | Buy | 934,624 | $42.95 | $40,142,100.80 | |
| 11/9/2015 | Felix Baker | Director | Buy | 507,300 | $43.76 | $22,199,448.00 | |
| 11/6/2015 | Eric Dobmeier | COO | Sell | 17,452 | $42.50 | $741,710.00 | |
| 11/6/2015 | Felix Baker | Director | Buy | 417,924 | $41.94 | $17,527,732.56 | |
| 11/5/2015 | David W Gryska | Director | Sell | 10,000 | $43.57 | $435,700.00 | |
| 11/4/2015 | Clay B. Siegall | CEO | Sell | 3,718 | $43.14 | $160,394.52 | |
| 10/5/2015 | Clay B. Siegall | CEO | Sell | 3,718 | $41.30 | $153,553.40 | |
| 9/3/2015 | Clay B. Siegall | CEO | Sell | 3,718 | $40.12 | $149,166.16 | |
| 8/20/2015 | Clay B. Siegall | CEO | Sell | 31,754 | $42.02 | $1,334,303.08 | |
| 8/20/2015 | Darren S. Cline | SVP | Sell | 2,231 | $42.02 | $93,746.62 | |
| 8/20/2015 | Eric Dobmeier | COO | Sell | 8,548 | $42.02 | $359,186.96 | |
| 8/20/2015 | Jonathan G. Drachman | CMO | Sell | 4,462 | $42.02 | $187,493.24 | |
| 8/20/2015 | Todd E. Simpson | CFO | Sell | 5,825 | $42.02 | $244,766.50 | |
| 8/20/2015 | Vaughn B. Himes | EVP | Sell | 5,997 | $42.02 | $251,993.94 | |
| 7/6/2015 | Clay B Siegall | CEO | Sell | 3,718 | $46.94 | $174,522.92 | |
| 6/3/2015 | Clay B Siegall | CEO | Sell | 3,718 | $45.72 | $169,986.96 | |
| 5/21/2015 | Felix Baker | Director | Buy | 950,886 | $42.49 | $40,403,146.14 | |
| 5/8/2015 | Eric Dobmeier | COO | Sell | 17,074 | $40.38 | $689,448.12 | |
| 5/7/2015 | Felix Baker | Director | Buy | 1,032,664 | $35.56 | $36,721,531.84 | |
| 3/10/2015 | Felix Baker | Director | Buy | 285,036 | $34.66 | $9,879,347.76 | |
| 3/9/2015 | Felix Baker | Director | Buy | 275,717 | $34.66 | $9,556,351.22 | |
| 3/4/2015 | Felix Baker | Director | Buy | 448,841 | $34.84 | $15,637,620.44 | |
| 2/25/2015 | Felix Baker | Director | Buy | 281,115 | $33.92 | $9,535,420.80 | |
| 1/6/2015 | Clay B Siegall | CEO | Sell | 16,804 | $31.80 | $534,367.20 | |
| 12/16/2014 | Felix Baker | Director | Buy | 2,883,378 | $31.86 | $91,864,423.08 | |
| 12/10/2014 | Felix Baker | Director | Buy | 1,247,896 | $33.82 | $42,203,842.72 | |
| 12/9/2014 | Felix Baker | Director | Buy | 128,430 | $34.16 | $4,387,168.80 | |
| 12/8/2014 | Felix Baker | Director | Buy | 465,316 | $32.93 | $15,322,855.88 | |
| 11/12/2014 | Vaughn B Himes | EVP | Sell | 10,000 | $37.52 | $375,200.00 | |
| 11/10/2014 | Felix Baker | Director | Buy | 1,653,925 | $34.56 | $57,159,648.00 | |
| 9/4/2014 | Clay B Siegall | CEO | Sell | 5,600 | $42.54 | $238,224.00 | |
| 8/12/2014 | Clay B Siegall | CEO | Sell | 11,200 | $40.38 | $452,256.00 | |
| 8/11/2014 | Clay B Siegall | CEO | Sell | 2,700 | $40.05 | $108,135.00 | |
| 6/13/2014 | Felix Baker | Director | Buy | 216,595 | $39.92 | $8,646,472.40 | |
| 6/10/2014 | Clay B Siegall | CEO | Sell | 11,200 | $40.14 | $449,568.00 | |
| 6/9/2014 | Felix Baker | Director | Buy | 546,252 | $38.16 | $20,844,976.32 | |
| 6/4/2014 | Felix Baker | Director | Buy | 281,963 | $34.86 | $9,829,230.18 | |
| 5/16/2014 | Felix Baker | Director | Buy | 189,611 | $34.07 | $6,460,046.77 | |
| 4/3/2014 | Clay Siegall | CEO | Sell | 5,600 | $43.34 | $242,704.00 | |
| 2/18/2014 | Clay Siegall | CEO | Sell | 100,000 | $51.97 | $5,197,000.00 | |
| 1/21/2014 | Eric Dobmeier | COO | Sell | 56,010 | $47.92 | $2,683,999.20 | |
| 1/16/2014 | Jonathan Drachman | CMO | Sell | 1,201 | $45.75 | $54,945.75 | |
| 12/16/2013 | Felix Baker | Director | Buy | 407,078 | $39.66 | $16,144,713.48 | |
| 12/5/2013 | Felix Baker | Director | Buy | 1,005,901 | $43.19 | $43,444,864.19 | |
| 10/1/2013 | Clay B Siegall | CEO | Sell | 2,000 | $43.87 | $87,740.00 | |
| 9/10/2013 | Eric Dobmeier | COO | Sell | 42,000 | $46.40 | $1,948,800.00 | |
| 9/5/2013 | Eric Dobmeier | COO | Sell | 75,000 | $42.64 | $3,198,000.00 | |
| 9/3/2013 | Clay B Siegall | CEO | Sell | 102,000 | $43.90 | $4,477,800.00 | |
| 9/3/2013 | David W Gryska | Director | Sell | 10,000 | $42.48 | $424,800.00 | |
| 8/27/2013 | Todd Simpson | CFO | Sell | 37,763 | $41.45 | $1,565,276.35 | |
| 8/19/2013 | Clay Siegall | CEO | Sell | 7,653 | $40.91 | $313,084.23 | |
| 8/19/2013 | Eric Dobmeier | COO | Sell | 3,328 | $40.91 | $136,148.48 | |
| 8/19/2013 | Vaughn Himes | EVP | Sell | 1,736 | $40.91 | $71,019.76 | |
| 8/1/2013 | Clay B Siegall | CEO | Sell | 2,000 | $40.03 | $80,060.00 | |
| 7/12/2013 | Todd E Simpson | CFO | Sell | 92,527 | $37.45 | $3,465,136.15 | |
| 7/1/2013 | Clay B Siegall | CEO | Sell | 2,000 | $32.59 | $65,180.00 | |
| 6/14/2013 | Srinivas Akkaraju | Director | Sell | 5,000 | $32.75 | $163,750.00 | |
| 6/13/2013 | Vaughn B Himes | EVP | Sell | 10,000 | $32.11 | $321,100.00 | |
| 6/3/2013 | Clay B Siegall | CEO | Sell | 2,000 | $33.88 | $67,760.00 | |
| 5/10/2013 | Srinivas Akkaraju | Director | Sell | 17,500 | $37.17 | $650,475.00 | |
| 3/6/2013 | Eric Dobmeier | COO | Sell | 100,000 | $29.68 | $2,968,000.00 | |
| 2/25/2013 | David W Gryska | Director | Sell | 10,000 | $27.17 | $271,700.00 | |
| 2/1/2013 | Clay B Siegall | CEO | Sell | 2,000 | $29.61 | $59,220.00 | |
| 1/15/2013 | Thomas C Reynolds | Insider | Sell | 125,079 | $28.00 | $3,502,212.00 | |
| 11/1/2012 | Clay B Siegall | CEO | Sell | 8,250 | $25.51 | $210,457.50 | |
| 9/4/2012 | Clay B Siegall | CEO | Sell | 8,250 | $26.54 | $218,955.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Seattle Genetics (NASDAQ:SGEN)
Latest Headlines for Seattle Genetics (NASDAQ:SGEN)
| Source: |
|
| Date | Headline |
|---|
 | $107.20 Million in Sales Expected for Seattle Genetics, Inc. (SGEN) This Quarter
www.americanbankingnews.com - July 19 at 4:54 PM |
| Analysts Expect Seattle Genetics, Inc. (SGEN) to Announce -$0.43 EPS
www.americanbankingnews.com - July 17 at 10:54 AM |
| Research Analysts Set Expectations for Seattle Genetics, Inc.'s Q3 2017 Earnings (SGEN)
www.americanbankingnews.com - July 17 at 8:11 AM |
| Seattle Genetics, Inc. (NASDAQ:SGEN) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 14 at 9:06 AM |
| Insider Selling: Seattle Genetics, Inc. (NASDAQ:SGEN) CEO Sells 10,423 Shares of Stock
www.americanbankingnews.com - July 7 at 8:16 PM |
 | Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 27, 2017
finance.yahoo.com - July 6 at 8:55 AM |
| FY2018 EPS Estimates for Seattle Genetics, Inc. Lowered by Analyst (SGEN)
www.americanbankingnews.com - June 29 at 11:36 AM |
| BidaskClub Lowers Seattle Genetics, Inc. (SGEN) to Sell
www.americanbankingnews.com - June 28 at 4:56 PM |
 | FBT's Underlying Holdings Could Mean 11% Gain Potential - Nasdaq
www.nasdaq.com - June 28 at 3:23 PM |
| Seattle Genetics (SGEN) Reports Positive Data for Adcetris - Nasdaq
www.nasdaq.com - June 28 at 8:18 AM |
| Seattle Genetics' (SGEN) Outperform Rating Reiterated at William Blair
www.americanbankingnews.com - June 28 at 7:32 AM |
| Analysts Issue Forecasts for Seattle Genetics, Inc.'s Q2 2017 Earnings (SGEN)
www.americanbankingnews.com - June 28 at 7:24 AM |
 | UPDATE 1-Seattle Genetics, Takeda lymphoma drug success fails
www.businessinsider.com - June 28 at 12:51 AM |
| Seattle Genetics (SGEN) Reports Positive Data for Adcetris
finance.yahoo.com - June 27 at 7:51 PM |
| UPDATE 2-Seattle Genetics slumps as cancer drug data fails to impress
www.businessinsider.com - June 27 at 8:15 AM |
 | Form 8-K SEATTLE GENETICS INC For: Jun 26
www.streetinsider.com - June 27 at 8:15 AM |
 | Seattle Genetics Inc. (SGEN) Dropped After Phase 3 Study Results Released
www.rttnews.com - June 27 at 8:15 AM |
 | Seattle Genetics preps for FDA approval of cancer drug that could push sales past $1B
www.bizjournals.com - June 27 at 8:15 AM |
| J.P. Morgan Gives Thoughts on Seattle Genetics, Inc. (SGEN) Following Phase 3 Results
finance.yahoo.com - June 27 at 8:15 AM |
| Seattle Genetics slumps as cancer drug data fails to impress
finance.yahoo.com - June 27 at 8:15 AM |
| Seattle Genetics Enters Oversold Territory (SGEN) - Nasdaq
www.nasdaq.com - June 27 at 8:15 AM |
| Today's Research Reports on Trending Tickers: Exelixis and Seattle Genetics
finance.yahoo.com - June 27 at 8:15 AM |
| J P Morgan Chase & Co Reiterates "Neutral" Rating for Seattle Genetics, Inc. (SGEN)
www.americanbankingnews.com - June 27 at 8:06 AM |
| Jonathan G. Drachman Sells 10,000 Shares of Seattle Genetics, Inc. (SGEN) Stock
www.americanbankingnews.com - June 26 at 7:39 PM |
 | Why Frontier Communications, Seattle Genetics, and Arconic Slumped Today
www.fool.com - June 26 at 5:07 PM |
| Why Shares of Seattle Genetics, Inc. Got Whacked Today
www.fool.com - June 26 at 2:16 PM |
| Seattle Genetics' (SGEN) Hold Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - June 26 at 10:31 AM |
| Seattle Genetics' (SGEN) Hold Rating Reiterated at Barclays PLC
www.americanbankingnews.com - June 23 at 11:35 AM |
| Seattle Genetics (SGEN) Announces Submission of Supplemental Biologics License ...
www.streetinsider.com - June 22 at 6:21 PM |
 | BRIEF-Seattle Genetics submits supplemental biologics license application to fda for Adcetris
www.reuters.com - June 22 at 6:21 PM |
| Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma
finance.yahoo.com - June 22 at 6:21 PM |
| Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug
finance.yahoo.com - June 22 at 1:19 PM |
| Seattle Genetics, Inc. (SGEN) Forecasted to Post Q3 2017 Earnings of ($0.19) Per Share
www.americanbankingnews.com - June 22 at 8:34 AM |
| Research Analysts Offer Predictions for Seattle Genetics, Inc.'s FY2020 Earnings (SGEN)
www.americanbankingnews.com - June 21 at 3:20 PM |
| Seattle Genetics, Inc. (SGEN) Earns Overweight Rating from Morgan Stanley
www.americanbankingnews.com - June 21 at 10:04 AM |
| Seattle Genetics, Inc. (SGEN) Expected to Post Earnings of -$0.44 Per Share
www.americanbankingnews.com - June 21 at 8:04 AM |
| Seattle Genetics (SGEN) Announces Submission of Supplemental ... - StreetInsider.com
www.streetinsider.com - June 21 at 5:15 AM |
| Seattle Genetics, Inc. (SGEN) Stock Rating Reaffirmed by J P Morgan Chase & Co
www.americanbankingnews.com - June 20 at 11:08 AM |
| Seattle Genetics, Inc. (SGEN) Price Target Raised to $66.00 at Leerink Swann
www.americanbankingnews.com - June 20 at 8:10 AM |
| Needham & Company Reiterates Buy Rating and $72 PT on Seattle Genetics (SGEN) Following Discontinuation of ... - StreetInsider.com
www.streetinsider.com - June 20 at 7:17 AM |
| AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN ... - Nasdaq
www.nasdaq.com - June 20 at 7:17 AM |
| Seattle Genetics (SGEN) Reports Discontinuation of Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A ... - StreetInsider.com
www.streetinsider.com - June 20 at 7:17 AM |
 | Seattle Genetics suspends trial of leukemia treatment after data showed higher rate of death - MarketWatch
www.marketwatch.com - June 20 at 7:17 AM |
| Cantor Fitzgerald Analysts Give Seattle Genetics, Inc. (SGEN) a $43.00 Price Target
www.americanbankingnews.com - June 19 at 3:16 PM |
| Seattle Genetics, Inc. (SGEN) Given "Hold" Rating at Cowen and Company
www.americanbankingnews.com - June 19 at 1:32 PM |
| Seattle Genetics, Inc. (SGEN) PT Lowered to $5.62 at Piper Jaffray Companies
www.americanbankingnews.com - June 19 at 11:34 AM |
| Seattle Genetics' (SGEN) Hold Rating Reiterated at Cann
www.americanbankingnews.com - June 19 at 11:34 AM |
| BRIEF-Seattle Genetics discontinues Phase 3 trial of vadastuximab talirine
www.reuters.com - June 19 at 9:44 AM |
| Seattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A) in Frontline Acute Myeloid Leukemia
finance.yahoo.com - June 19 at 9:44 AM |
| Seattle Genetics suspends trial of leukemia treatment after data showed higher rate of death
finance.yahoo.com - June 19 at 9:44 AM |
Seattle Genetics (SGEN) Chart for Sunday, July, 23, 2017
